Dapansutrile-based Therapies for Chronic Diseases

Expanding the application of dapansutrile beyond melanoma treatment to address chronic respiratory diseases, cardiovascular diseases, neurodegenerative disorders, inflammatory bowel diseases, and osteoporosis.

The original patent disclosed methods for treating melanoma using dapansutrile. However, the patent's scope was limited to cancer treatment. The new inventive concept addresses the need for effective therapies in various chronic diseases, where inflammation and tissue damage play a significant role.

The new inventive concept leverages the anti-inflammatory and tissue-protective properties of dapansutrile to develop novel therapeutic approaches for chronic diseases. The system and method claims describe the administration of dapansutrile to subjects suffering from or at risk of these diseases, thereby reducing inflammation, promoting tissue healing, and improving disease outcomes. The composition claim outlines the use of dapansutrile as an active ingredient in formulations tailored to specific diseases.

The new claims introduce a significant shift in the application of dapansutrile, moving beyond cancer treatment to address a range of chronic diseases. This expansion of therapeutic scope is non-obvious and represents a substantial innovation over the original patent.

Alternative formulations, dosing regimens, and delivery methods could be explored to optimize the efficacy and safety of dapansutrile-based therapies. Additionally, combination therapies incorporating dapansutrile with other agents could be developed to enhance treatment outcomes.

The new inventive concept has significant commercial potential in the pharmaceutical industry, with applications in multiple disease areas and potential for market growth. The target markets include companies developing therapies for chronic respiratory diseases, cardiovascular diseases, neurodegenerative disorders, inflammatory bowel diseases, and osteoporosis.